Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Gains from Investment Securities (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Gains from Investment Securities for 12 consecutive years, with $2.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Investment Securities fell 8.95% year-over-year to $2.2 million, compared with a TTM value of $2.2 million through Sep 2025, down 8.95%, and an annual FY2024 reading of $14.6 million, up 12.45% over the prior year.
  • Gains from Investment Securities was $2.2 million for Q3 2025 at CytomX Therapeutics, down from $3.2 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $16.8 million in Q1 2025 and bottomed at $303341.0 in Q1 2024.
  • Average Gains from Investment Securities over 5 years is $8.4 million, with a median of $12.0 million recorded in 2021.
  • The sharpest move saw Gains from Investment Securities crashed 97.85% in 2024, then skyrocketed 5431.42% in 2025.
  • Year by year, Gains from Investment Securities stood at $12.2 million in 2021, then grew by 9.0% to $13.3 million in 2022, then dropped by 2.56% to $12.9 million in 2023, then increased by 12.45% to $14.6 million in 2024, then tumbled by 85.18% to $2.2 million in 2025.
  • Business Quant data shows Gains from Investment Securities for CTMX at $2.2 million in Q3 2025, $3.2 million in Q2 2025, and $16.8 million in Q1 2025.